1. Home
  2. About the Journal
  3. Editorial Policies

Editorial Policies

Focus and Scope

Indonesian Journal of Cancer ( p-ISSN: 1978-3744 e-ISSN: 2355-6811 ) is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following focus and scope: 

  1. Cancer management,
  2. Cancer prevention,
  3. Cancer etiology,
  4. Epidemiology,
  5. Molecular oncology,
  6. Cancer diagnosis and therapy,
  7. Tumor pathology,
  8. Surgical oncology,
  9. Medical oncology,
  10. Radiation oncology,
  11. Interventional radiology,
  12. As well as early detection.


Indonesian Journal of Cancer is accredited  by National Journal Accreditation (ARJUNA) Managed by Ministry of Education, Culture, Research and Technology, the Republic of Indonesia with Second Grade (SINTA 2) (No. 200/M/KPT/2020).

Section Policies

Editorial

  • Checked Open Submissions
  • Checked Indexed
  • Checked Peer Reviewed

Research Article

  • Checked Open Submissions
  • Checked Indexed
  • Checked Peer Reviewed

Systematic Literature Review

  • Checked Open Submissions
  • Checked Indexed
  • Checked Peer Reviewed

Case Report

  • Checked Open Submissions
  • Checked Indexed
  • Checked Peer Reviewed

Review Article

  • Checked Open Submissions
  • Checked Indexed
  • Checked Peer Reviewed

Peer Review Process

All manuscripts submitted to Indonesian Journal of Cancer (IJoC) will undergo an initial review by the Editor-in-Chief/Managing Editor. Submission received without the necessary accompanying material such as cover letter, full manuscript in the correct format, signed authors agreement, and ethical approval will be returned to the author(s) and will not be evaluated for further peer-review process. Submissions that are in line with the scope of the journal and meet the submission requirements will undergo a peer-review process.

Manuscripts that pass the first evaluation will be sent for peer-review to at least two independent experts in the field. This review process is double-blind, where both the author(s) and the reviewer(s) identities are kept confidential. While we try to avoid delays, this part of the process relies on the availability and cooperation of the reviewers and can take considerable time.

Upon receipt of the reviews, the manuscript is evaluated in detail by the editorial team taking into account the reviewers' comments and recommendations. If the reviewers' opinions are conflicting, the article may be sent for further review. The final decision on the acceptance or rejection of a manuscript will be made by the Editor-in-Chief. The accepted manuscript will be checked by a copyeditor for language editing.

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Archiving

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. More...

About the Journal

Indonesian Journal of Cancer ( p-ISSN: 1978-3744 e-ISSN: 2355-6811 ), the official journal of Dharmais Cancer Hospital - National Cancer Center, is a peer-reviewed, quarterly, and open-access journal. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. 

Accreditation:  National Journal Accreditation (ARJUNA) Managed by Ministry of Education, Culture, Research and Technology, the Republic of Indonesia with Second Grade (SINTA 2) (No. 200/M/KPT/2020).

Address of the journal's OAI:
https://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/oai

Informed Consent

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Authors should disclose to these patients whether any potential identifiable material might be available via the internet as well as in print after publication. Nonessential identifying details should be omitted.

Indonesian Journal of Cancer decides that patient confidentiality is better guarded by having the authors archive the consent, and instead providing us with a written statement in the manuscript attesting that they have received and archived written patient consent. When informed consent has been obtained, it should be indicated later in the published article.

Indexing

Indonesian Journal of Cancer Indexed By

CrossrefScilitWorldcat GarudaGoogle Scholar ScilitNelitiMicrosoft

 

Publication Frequency

The Indonesian Journal of Cancer (IJoC) is published quarterly (in March, June, September, and December).

CrossCheck Information Page

CrossCheck is a multi-publisher initiative to screen published and submitted content for originality. Indonesian Journal of Cancer uses the iThenticate software to detect instances of overlapping and similar text in submitted manuscripts. Wherever you see the “CrossCheck Deposited” or “CrossCheck Depositor” logos, you can be reassured that the publisher whose content you are reading is committed to actively combating plagiarism and publishing original research. To find out more about CrossCheck visit http://www.crossref.org/crosscheck.html

iThenticate is also available to authors and researchers who wish to check their papers before submission.  iThenticate compares submitted documents to extensive data repositories to create a comprehensive Similarity Report, which highlights and provides links to any significant text matches, helping to ensure that you are submitting an original and well-attributed document. iThenticate for Researchers is a separate service to CrossCheck.



All articles and issues in Indonesian Journal of Cancer have unique DOI number registered in Crossref.
Crossref Similarity Check logo

Plagiarism

Papers submitted to Indonesian Journal of Cancer (IJoC) will be screened for plagiarism using iThenticate plagiarism detection tools. IJoC will immediately return the manuscript to the author(s) containing plagiarism or self-plagiarism.

Before articles are submitted to reviewers, they are first checked for similarity/plagiarism by a member of the editorial team. Papers submitted to IJoC must have a similarity level of less than 20%.

Plagiarism is the exposure of another person’s thoughts or words as though they were your own, without permission, credit, or acknowledgment, or by failing to cite the sources properly. Plagiarism can take diverse forms, from literal copying to paraphrasing the work of another. In order to properly judge whether an author has plagiarized, we emphasize the following possible situations:

  • Literal copying – An author copies another author’s work word for word, in whole or in part, without permission and without acknowledging or citing the original source. This practice can be identified by comparing the original source and the manuscript/work suspected to be plagiarized.
  • Substantial copying – An author reproduces a substantial part of another author’s work, without permission and without acknowledging or citing the original source. The term ‘substantial’ can be understood both in terms of quality and quantity, being often used in the context of intellectual property. ‘Quality’ refers to the relative value of the copied text in comparison to the work as a whole.
  • Paraphrasing – An author takes ideas, words, or phrases from a source and crafts them into new sentences within their own writing. This practice becomes unethical when the author does not properly cite or does not acknowledge the original work/author. This form of plagiarism is the more difficult form to be identified.

Retraction

The papers published in Indonesian Journal of Cancer (IJoC) will be considered to retract in the publication if :

  1. They have clear evidence that the findings are unreliable, either as a result of misconduct (e.g. data fabrication) or honest error (e.g. miscalculation or experimental error)
  2. The findings have previously been published elsewhere without proper crossreferencing, permission, or justification (i.e. cases of redundant publication)
  3. It constitutes plagiarism
  4. It reports unethical research

The mechanism of retraction follows the Retraction Guidelines of Committee on Publication Ethics (COPE) which can be accessed at https://publicationethics.org/files/retraction%20guidelines.pdf.

Content License

All materials are free to be copied and redistributed in any medium or format. However, appropriate credit should be given. The material may not be used for commercial purposes. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References Management

Every article accepted by Indonesian Journal of Cancer (IJoC) uses references management software (e.g., Mendeley or Zotero)

Article Processing Charge

Indonesian Journal of Cancer is an open-access journal. Since the manuscript submission year 2007, Authors should not pay some processing and submission fees for article processing (free of charge).

 

Authorship Consideration

Indonesian Journal of Cancer (IJoC) considers an author as a person who has substantially contributed to all stages of research that the manuscript reports its result. On the other hand, all authors who are listed in a manuscript have contributed to the research and the manuscript submitted to the journal. There are many different definitions of authorship among different bodies that oversee authorship rights and responsibilities. The COPE defines authorship as “The term authorship can refer to the creator or originator of an idea (eg, the author of the theory of relativity) or the individual or individuals who develop and bring to fruition the product that disseminates intellectual or creative works (eg, the author of a poem or a scholarly article).” International Committee of Medical Journal Editors (ICMJE) bases the authorship on the following four criteria:

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work
  2. Drafting the work or revising it critically for important intellectual content
  3. Final approval of the version to be published
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved